OA11589A - Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. - Google Patents

Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. Download PDF

Info

Publication number
OA11589A
OA11589A OA1200100027A OA1200100027A OA11589A OA 11589 A OA11589 A OA 11589A OA 1200100027 A OA1200100027 A OA 1200100027A OA 1200100027 A OA1200100027 A OA 1200100027A OA 11589 A OA11589 A OA 11589A
Authority
OA
OAPI
Prior art keywords
tetrahydro
sulfonylamino
dibenzofuran
acid
hydroxy
Prior art date
Application number
OA1200100027A
Other languages
English (en)
Inventor
Patrick Michael O'brien
Joseph Armand Picard
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA11589A publication Critical patent/OA11589A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
    • H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/31—Distributed metering or calculation of charges
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/49—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/80—Rating or billing plans; Tariff determination aspects
    • H04M15/8044—Least cost routing
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
    • H04M15/83—Notification aspects
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/01—Details of billing arrangements
    • H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/46—Connection to several service providers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
    • H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
    • H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
OA1200100027A 1998-07-30 1999-06-02 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. OA11589A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9500698P 1998-07-30 1998-07-30

Publications (1)

Publication Number Publication Date
OA11589A true OA11589A (en) 2004-07-30

Family

ID=22248526

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100027A OA11589A (en) 1998-07-30 1999-06-02 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.

Country Status (32)

Country Link
US (2) US6420408B1 (ru)
EP (1) EP1100792B1 (ru)
JP (1) JP2002521478A (ru)
KR (1) KR20010072089A (ru)
CN (1) CN1310716A (ru)
AP (1) AP2001002037A0 (ru)
AT (1) ATE261954T1 (ru)
AU (1) AU758619B2 (ru)
BG (1) BG105185A (ru)
BR (1) BR9912600A (ru)
CA (1) CA2335077A1 (ru)
DE (1) DE69915634T2 (ru)
DK (1) DK1100792T3 (ru)
EA (1) EA200100158A1 (ru)
EE (1) EE200100063A (ru)
ES (1) ES2216614T3 (ru)
GE (1) GEP20033052B (ru)
HR (1) HRP20010078A2 (ru)
HU (1) HUP0102714A3 (ru)
ID (1) ID27192A (ru)
IL (1) IL140746A0 (ru)
IS (1) IS5810A (ru)
NO (1) NO20010479L (ru)
NZ (1) NZ509439A (ru)
OA (1) OA11589A (ru)
PL (1) PL345776A1 (ru)
PT (1) PT1100792E (ru)
SK (1) SK1192001A3 (ru)
TR (1) TR200100239T2 (ru)
WO (1) WO2000006561A1 (ru)
YU (1) YU6701A (ru)
ZA (1) ZA200100455B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
BR0211698A (pt) * 2001-08-03 2004-11-09 Schering Corp Inibidores de gama-secretase
WO2003032974A2 (en) * 2001-10-12 2003-04-24 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
CA2486581A1 (en) * 2002-06-11 2003-12-18 Wyeth Substituted phenylsulfonamide inhibitors of beta amyloid production
WO2004006912A2 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
US7524938B2 (en) 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US20060112494A1 (en) * 2004-12-01 2006-06-01 David Oppong Method of protecting an animal skin product from metalloproteinase activity
BRPI0807256A2 (pt) * 2007-02-23 2014-07-22 Yeda Res & Dev "composição com fórmula geral i, composto com a fórmula ii, anticorpo, método de produção de inibidor de metaloproteinase,composição farmacêutica, método de tratamento de doença associada a atividade incompatível ou anormal de metaloproteinas, método de inibição da atividade da metaloproteinase matriz em uma célula"
US8012947B2 (en) * 2007-03-15 2011-09-06 Hospital For Special Surgery Methods and compositions for promoting wound healing
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
CA2676946A1 (en) 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
JP2013538821A (ja) 2010-09-24 2013-10-17 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
WO2021147882A1 (zh) * 2020-01-21 2021-07-29 深圳信立泰药业股份有限公司 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH517068A (de) * 1969-07-09 1971-12-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten
CH542835A (de) * 1970-03-20 1973-10-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäuren und ihren Salzen
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
WO1996038434A1 (en) 1995-06-02 1996-12-05 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
US5883940A (en) 1996-07-01 1999-03-16 Teledynamics Group, Inc. Interactive method and apparatus for the generation of leads
WO1998006711A1 (en) 1996-08-16 1998-02-19 Warner-Lambert Company Butyric acid matrix metalloproteinase inhibitors
AU736347B2 (en) * 1996-09-04 2001-07-26 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO1998009934A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
KR20000049196A (ko) * 1996-10-16 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 및 ｔａｃｅ 억제제로서 오르토-설폰아미도 아릴 하이드록삼산의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
US20020169164A1 (en) 2002-11-14
HRP20010078A2 (en) 2002-02-28
US6492422B2 (en) 2002-12-10
EA200100158A1 (ru) 2001-08-27
DE69915634T2 (de) 2004-08-12
NO20010479D0 (no) 2001-01-29
TR200100239T2 (tr) 2001-05-21
SK1192001A3 (en) 2002-02-05
AP2001002037A0 (en) 2001-03-31
HUP0102714A2 (hu) 2002-01-28
ATE261954T1 (de) 2004-04-15
DE69915634D1 (de) 2004-04-22
CA2335077A1 (en) 2000-02-10
BR9912600A (pt) 2001-05-02
KR20010072089A (ko) 2001-07-31
NZ509439A (en) 2002-10-25
EP1100792B1 (en) 2004-03-17
ID27192A (id) 2001-03-08
PT1100792E (pt) 2004-08-31
GEP20033052B (en) 2003-08-25
BG105185A (en) 2002-04-30
NO20010479L (no) 2001-01-29
CN1310716A (zh) 2001-08-29
IS5810A (is) 2001-01-12
IL140746A0 (en) 2002-02-10
ZA200100455B (en) 2002-01-16
ES2216614T3 (es) 2004-10-16
YU6701A (sh) 2003-12-31
EP1100792A1 (en) 2001-05-23
EE200100063A (et) 2002-06-17
AU758619B2 (en) 2003-03-27
JP2002521478A (ja) 2002-07-16
US6420408B1 (en) 2002-07-16
AU4329299A (en) 2000-02-21
PL345776A1 (en) 2002-01-02
HUP0102714A3 (en) 2003-01-28
WO2000006561A1 (en) 2000-02-10
DK1100792T3 (da) 2004-07-05

Similar Documents

Publication Publication Date Title
US6420408B1 (en) Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
US6350885B1 (en) Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
US6399612B1 (en) Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6117869A (en) Compounds for and methods of inhibiting matrix metalloproteinases
US6624196B2 (en) Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6265432B1 (en) Flourine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6037361A (en) Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases
EP0876343B1 (en) Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases
US6677355B1 (en) Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
MXPA00012948A (en) Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
CZ2001302A3 (cs) Tricyklické sulfonamidy a jejich deriváty jako inhibitory matricových metaloproteináz
CA2233560C (en) Sulfonamide inhibitors of matrix metalloproteinases
MXPA98003315A (en) Queto aromatic acids and their derivatives as inhibitors of metaloproteinases mat
CA2236096A1 (en) Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases